Wave Life Sciences Announces CEO's Participation in Conferences
Wave Life Sciences Ltd. (NASDAQ: WVE), a pioneering biotech firm dedicated to the transformative potential of RNA medicines, is thrilled to share that its President and CEO, Paul Bolno, MD, MBA, will participate in two significant investor conferences this December. These events present an excellent opportunity for investors and stakeholders to gain insights into the company's groundbreaking work in the field of RNA therapeutics.
Details of Upcoming Conferences
The first event is the 7th Annual Evercore HealthCONx Conference, scheduled for Tuesday, December 3. During the conference, which features an analyst-led fireside chat, Dr. Bolno will discuss Wave's innovative approach to RNA medicine and the company’s progress toward achieving its ambitious objectives.
Insights from the Evercore HealthCONx Conference
This conference is known for its focus on critical developments within the healthcare sector. Participants can expect an in-depth look at how Wave is leveraging its proprietary RNA-targeting platform to optimize therapeutic solutions for patients.
Participation in the Citi 2024 Global Healthcare Conference
The second event is the Citi 2024 Global Healthcare Conference, which takes place on Wednesday, December 4. Dr. Bolno will join a panel discussing Neuromuscular Disorders at 1:00 p.m. ET. The panel aims to shed light on the latest advancements in treatments and what the future may hold for patients with such conditions.
Focus on Neuromuscular Disorders
Through this panel, attendees will learn about Wave Life Sciences’ efforts in developing targeted therapies for neuromuscular disorders, further emphasizing the company's key mission of addressing significant medical needs through innovative science.
Online Access and Replay Information
For those unable to attend in person, live webcasts of these important presentations will be available on the Investor Events page of Wave Life Sciences’ official website. Furthermore, replays of the talks will be archived online for limited access, allowing broader engagement with Wave's mission and progress.
About Wave Life Sciences
Headquartered in Cambridge, MA, Wave Life Sciences is committed to unlocking the wide-ranging potential of RNA medicines. Using its PRISM platform, the company is at the forefront of RNA research, integrating various modalities and harnessing deep insights from human genetics to produce viable therapies.
The pipeline features crucial programs aimed at addressing Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, Huntington's disease, and a preclinical initiative in combating obesity. Driven by the intent to “Reimagine Possible,” Wave Life Sciences seeks to empower humanity by alleviating the burdens of disease through groundbreaking medical advancements.
Company Contacts
For more inquiries related to investor relations, please reach out to:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
For media requests, contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
Frequently Asked Questions
What is Wave Life Sciences focusing on at the conferences?
Wave Life Sciences will focus on its recent advancements in RNA medicine and its ongoing research programs for various diseases.
When and where are the conferences taking place?
The conferences will occur on December 3rd and December 4th, with participation from prominent healthcare investors and analysts.
How can I attend the webcasts of these conferences?
The webcasts will be accessible on the Investor Events page of Wave Life Sciences' website during the conference dates.
What significant diseases is Wave Life Sciences targeting?
Wave is developing therapies for Duchenne muscular dystrophy, Huntington's disease, and other important medical conditions.
Who should be contacted for investor inquiries?
Kate Rausch is the point of contact for investor relations and can be reached via email or phone.
